Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib trial of Odiparcil in children with Mucopolysaccharidosis VI (MPS VI)

Trial Profile

Phase Ib trial of Odiparcil in children with Mucopolysaccharidosis VI (MPS VI)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odiparcil (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions
  • Acronyms SAFE-KIDDS
  • Most Recent Events

    • 15 May 2018 According to an Inventiva Pharma media release, company plans to launch this trial during the second semester 2018 and designation of MPS VI as rare pediatric disease by the FDA is expected in the third quarter 2018
    • 19 Apr 2018 New trial record
    • 13 Apr 2018 According to an Inventiva Pharma media release, results from this trial are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top